tradingkey.logo

Ginkgo Bioworks Holdings Inc

DNA
View Detailed Chart

11.420USD

+0.350+3.16%
Close 09/18, 16:00ETQuotes delayed by 15 min
632.96MMarket Cap
LossP/E TTM

Ginkgo Bioworks Holdings Inc

11.420

+0.350+3.16%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.16%

5 Days

+9.39%

1 Month

-17.25%

6 Months

+56.87%

Year to Date

+16.29%

1 Year

+54.12%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Sell. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
208 / 506
Overall Ranking
335 / 4721
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Sell
Current Rating
11.333
Target Price
+2.38%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
Undervalued
The company’s latest PE is -1.98, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 36.64M shares, decreasing 12.19% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 3.58M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
Ticker SymbolDNA
CompanyGinkgo Bioworks Holdings Inc
CEODr. Jason Kelly
Websitehttps://investors.ginkgobioworks.com/
KeyAI